Drug intelligence / Profile preview

ME104

Development stage: Preclinical
Lead developer: M's Science
Modality: Small Molecules
Administration: Ophthalmic

Overview

ME104 is a preclinical-stage small molecule and modified oligosaccharide that acts as a heparan sulfate analog. Developed by M's Science Corporation, it is formulated as an ophthalmic solution intended to promote corneal epithelial repair by modulating the heparan sulfate pathway. The drug is being developed for the treatment of ophthalmic conditions including neurotrophic keratitis and dry eye. Its mechanism involves mimicking endogenous heparan sulfate to facilitate the stabilization and activity of growth factors essential for corneal wound healing.

Other names: ME104 (ophthalmic solution)

Targets

HS (Heparan sulfate)

Beyond the preview

Go deeper on ME104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ME104.

Explore the full profile